Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.
There is no one-size-fits-all approach to treating cancer. Understanding how cancer cells evolve could help researchers develop more effective drugs.
As part of an effort to increase antibody efficacy, bispecific antibodies (bsAbs), which can bind two different antigens or epitopes are becoming an area of focus. Most bsABs in trial are cancer therapeutics and this article delves into their potential usage in cancer immunotherapy.
Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.
Researchers review recent advancements in nanomedicine treatment options for cardiovascular disease.